Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
225 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Wet (Neovascular / Exudative) Macular Degeneration Overview 9 Therapeutics Development 10 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 10 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis 11 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19 Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 23 Alcon, Inc. 23 Allergan, Inc. 24 AlphaMab Co., Ltd 25 Amakem NV 26 Avalanche Biotechnologies, Inc. 27 Bayer AG 28 BIOCAD 29 Boehringer Ingelheim GmbH 30 Charlesson LLC. 31 Circadian Technologies Limited 32 Clearside BioMedical, Inc. 33 EyeCyte, Inc. 34 F. Hoffmann-La Roche Ltd. 35 Genzyme Corporation 36 GlaxoSmithKline plc 37 iCo Therapeutics Inc. 38 Icon Bioscience, Inc. 39 Iconic Therapeutics, Inc. 40 Intas Pharmaceuticals Ltd. 41 Kala Pharmaceuticals, Inc. 42 Lpath, Inc. 43 Mesoblast Limited 44 Neurotech Pharmaceuticals, Inc. 45 Novartis AG 46 Ohr Pharmaceutical Inc. 47 Ophthotech Corp. 48 Oxford BioMedica plc 49 PanOptica, Inc. 50 Pfenex Inc. 51 Pfizer Inc. 52 pSivida Corp. 53 Quark Pharmaceuticals, Inc. 54 Regeneron Pharmaceuticals, Inc. 55 ReGenX Biosciences, LLC 56 Resolvyx Pharmaceuticals, Inc 57 Santen Pharmaceutical Co., Ltd. 58 Sanwa Kagaku Kenkyusho Co., Ltd. 59 Tacere Therapeutics, Inc. 60 ThromboGenics NV 61 TRACON Pharmaceuticals, Inc. 62 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Target 64 Assessment by Mechanism of Action 67 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 abicipar pegol - Drug Profile 74 aflibercept (recombinant) - Drug Profile 76 AGN-151200 - Drug Profile 79 ALG-1001 - Drug Profile 80 AMA-0428 - Drug Profile 82 ARC-1905 - Drug Profile 83 AVA-101 - Drug Profile 84 AVA-201 - Drug Profile 86 bertilimumab - Drug Profile 87 bevacizumab biosimilar - Drug Profile 89 BI-144807 - Drug Profile 90 C16Y Peptide - Drug Profile 91 CLT-005 - Drug Profile 92 conbercept - Drug Profile 93 DE-120 - Drug Profile 95 doxorubicin pegylated nanoparticle - Drug Profile 96 Drug for Wet Age Related Macular Degeneration - Drug Profile 97 EC-200 - Drug Profile 98 EC-400 - Drug Profile 99 ENV-705 - Drug Profile 100 fluocinolone acetonide - Drug Profile 101 GB-101 - Drug Profile 103 Gene Therapy for Wet Age-Related Macular Degeneration - Drug Profile 104 GZ-402663 - Drug Profile 105 hI-con1 - Drug Profile 106 LFG-316 - Drug Profile 107 Lpathomab - Drug Profile 109 LT-1009 - Drug Profile 110 MPC-MICRO-IO - Drug Profile 114 NM-9405 - Drug Profile 115 NT-503 - Drug Profile 116 NT-506 - Drug Profile 117 ocriplasmin (recombinant) - Drug Profile 118 OPT-302 - Drug Profile 121 PAN-90806 - Drug Profile 122 pazopanib hydrochloride - Drug Profile 124 pegpleranib sodium - Drug Profile 129 PF-05206388 - Drug Profile 131 PF-655 - Drug Profile 132 ranibizumab biosimilar - Drug Profile 134 ranibizumab biosimilar - Drug Profile 135 ranibizumab biosimilar - Drug Profile 136 REGN-2176-3 - Drug Profile 137 regorafenib - Drug Profile 138 RetinoStat - Drug Profile 141 RG-7716 - Drug Profile 142 RTH-258 - Drug Profile 143 RX-20001 - Drug Profile 145 SK-1011 - Drug Profile 146 Small Molecule to Inhibit Receptor Tyrosine Kinase for Wet Age-Related Macular Degeneration - Drug Profile 147 Small Molecules for Age Related Macular Degeneration - Drug Profile 148 Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile 149 Small Molecules to Inhibit VEGF for Wet AMD - Drug Profile 151 squalamine lactate - Drug Profile 153 TRC-105 - Drug Profile 156 triamcinolone acetonide - Drug Profile 158 TT-211 - Drug Profile 159 TT-231 - Drug Profile 160 X-82 - Drug Profile 161 XV-615 - Drug Profile 162 Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 163 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 209 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 210 Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 211 Featured News & Press Releases 211 Appendix 220 Methodology 220 Coverage 220 Secondary Research 220 Primary Research 220 Expert Panel Validation 220 Contact Us 221 Disclaimer 221
List of Tables Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2014 14 Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Development by Companies, H2 2014 (Contd..1) 24 Products under Development by Companies, H2 2014 (Contd..2) 25 Products under Development by Companies, H2 2014 (Contd..3) 26 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alcon, Inc., H2 2014 27 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan, Inc., H2 2014 28 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H2 2014 29 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2014 30 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H2 2014 31 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Bayer AG, H2 2014 32 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H2 2014 33 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2014 34 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2014 35 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H2 2014 36 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2014 37 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by EyeCyte, Inc., H2 2014 38 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 39 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Genzyme Corporation, H2 2014 40 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GlaxoSmithKline plc, H2 2014 41 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2014 42 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2014 43 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2014 44 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 45 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 46 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Lpath, Inc., H2 2014 47 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mesoblast Limited, H2 2014 48 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 49 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Novartis AG, H2 2014 50 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2014 51 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2014 52 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica plc, H2 2014 53 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2014 54 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2014 55 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2014 56 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2014 57 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 58 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 59 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ReGenX Biosciences, LLC, H2 2014 60 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2014 61 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 62 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2014 63 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tacere Therapeutics, Inc., H2 2014 64 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ThromboGenics NV, H2 2014 65 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 66 Assessment by Monotherapy Products, H2 2014 67 Number of Products by Stage and Target, H2 2014 69 Number of Products by Stage and Mechanism of Action, H2 2014 72 Number of Products by Stage and Route of Administration, H2 2014 75 Number of Products by Stage and Molecule Type, H2 2014 77 Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2014 167 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2014 213 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2014 214
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
